Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A meta-analysis

Urologia Internationalis

Volumn 91, Issue 1, 2013, Pages 10-18

  Dong, Yang ^a   Hao, Lin ^b   Shi, Zhenduo ^b   Wang, Gang ^b   Zhang, Zhiguo ^b   Han, Conghui ^a,b  

^a SOUTHEAST UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Benign prostatic hyperplasia; Cialis; Lower urinary tract symptoms; Meta analysis; Tadalafil

Indexed keywords

TADALAFIL;

ARTICLE; BACKACHE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; URINE FLOW RATE;

CARBOLINES; ERECTILE DYSFUNCTION; HUMANS; MALE; PATIENT SAFETY; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK; TREATMENT OUTCOME; URINARY TRACT; UROLOGIC DISEASES; UROLOGICAL AGENTS;

EID: 84880923969     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000351405     Document Type: Article

References (30)

1. Wei JT, Calhoun E, Jacobsen SJ: Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-1261.
2. Gacci M, Eardley I, Giuliano F, et al: Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-825.
3. McVary KT, Roehrborn CG, Avins AL, et al: Management of benign prostatic hyperplasia (BPH). American Urological Association website: http://www.auanet.org/content/ guidelines-and-quality-care/clinical-guidelines. cfm?sub=bph (updated 2010).
4. Rosen R, Altwein J, Boyle P, et al: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649.
5. Rosen RC: Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 2006; 16: 11-19.
6. Wang C: Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010; 20: 49-54.
7. Liu L, Zheng S, Han P, et al: Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. Urology 2011; 77: 123-129.
8. Gacci M, Corona G, Salvi M, et al: A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003.
9. Kedia GT, Uckert S, Jonas U, et al: The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008; 26: 603-609.
10. Uckert S, Hedlund P, Andersson KE, et al: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol 2006; 50: 1194-1207.
11. Carson CC 3rd: Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol Clin North Am 2007; 34: 507-515, vi.
12. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
13. McVary KT, Roehrborn CG, Kaminetsky JC, et al: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-1407.
14. Roehrborn CG, McVary KT, Elion-Mboussa A, et al: Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008; 180: 1228-1234.
15. Porst H, McVary KT, Montorsi F, et al: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727-735.
16. Dmochowski R, Roehrborn C, Klise S, et al: Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: A randomized, placebo controlled 12-week clinical trial. J Urol 2010; 183: 1092-1097.
17. Roehrborn CG, Kaminetsky JC, Auerbach SM, et al: Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010; 105: 502-507.
18. Kim SC, Park JK, Kim SW, et al: Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. Low Urin Tract Symptoms 2011; 3: 86-93.
19. Porst H, Kim ED, Casabe AR, et al: Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 1105-1113.
20. Egerdie RB, Auerbach S, Roehrborn CG, et al: Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012; 9: 271-281.
21. Oelke M, Giuliano F, Mirone V, et al: Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebocontrolled clinical trial. Eur Urol 2012; 61: 917-925.
22. Wong P, Lawrentschuk N, Bolton DM: Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr Opin Urol 2009; 19: 7-12.
23. Broderick GA, Brock GB, Roehrborn CG, et al: Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010; 75: 1452-1458.
24. Filippi S, Morelli A, Sandner P, et al: Characterization and functional role of androgendependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-1029.
25. Morelli A, Sarchielli E, Comeglio P, et al: Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011; 8: 2746-2760.
26. Beamon CR, Mazar C, Salkini MW, et al: The effect of sildenafil citrate on bladder outlet obstruction: A mouse model. BJU Int 2009; 104: 252-256.
27. Gacci M, Del Popolo G, Macchiarella A, et al: Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178: 2040-2043; discussion 2044.
28. Donatucci CF, Brock GB, Goldfischer ER, et al: Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1-year, open-label extension study. BJU Int 2011; 107: 1110-1116.
29. Kang DH, Lee JY, Chung JH, et al: Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg ondemand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract 2012; 66: 813-820.
30. Porst H, Rajfer J, Casabe A, et al: Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008; 5: 2160-2169.